Evidence map›Paper›PMID 40979017›Full record

ReviewCureus2025

Addressing Multidrug-Resistant Organisms (MDROs) Through Antimicrobial Stewardship in Nigeria: A Review of Challenges, Opportunities, and Strategies for Effective Implementation.

Daniel O Umoru, Chidinma V Muoghalu, Rebecca A Omachonu, Adeola S Bakare, Charles C Arukwe

Abstract readReview
In one paragraph

Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Daniel O UmoruPharmacy, National Hospital Abuja, Abuja, NGA.
Chidinma V MuoghaluBiochemistry and Nutrition, Nigeria Institute of Medical Research, Lagos, NGA.
Rebecca A OmachonuBiomedical Sciences, Keck Graduate Institute of Applied Life Sciences, Claremont, USA.
Adeola S BakarePharmacy, Citiserve Pharmacy, Lagos, NGA.
Charles C ArukwePharmacy, Abia State University Teaching Hospital, Aba, NGA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidrug-resistant organisms (MDROs) are a growing public health threat in Nigeria, driven by inappropriate antibiotic use, limited surveillance, and weak healthcare infrastructure. Antimicrobial stewardship programs (ASPs) are critical in addressing this challenge by promoting appropriate antibiotic use and reducing resistance. This scoping review synthesizes evidence published between 2018 and 2025, examining the challenges, opportunities, and strategies for implementing ASPs in Nigeria. Key challenges include inadequate diagnostic capacity, poor regulatory enforcement, and limited resources. Opportunities exist in leveraging technology, fostering international partnerships, and adopting the One Health approach. Proposed strategies include expanding diagnostic stewardship, increasing investment in laboratory infrastructure, enforcing antibiotic prescribing policies, integrating antimicrobial resistance (AMR) content into healthcare curricula, and launching targeted public awareness campaigns. Data visualization through figures and tables highlights resistance trends across common pathogens, conceptual ASP frameworks, implementation challenges, and the systematic review flowchart of study selection. The escalating burden of MDROs in Nigeria demands urgent and coordinated action. Strengthening antimicrobial stewardship through policy enforcement, infrastructure development, and education is essential to slow resistance and protect public health.

Indexed as

antibiotic resistanceantimicrobial resistanceantimicrobial stewardshipinfectious diseasemulti-drug resistant organism (mdro)nigeriaone healthsurveillance

Identifiers

PMID40979017
PMCPMC12445240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.